Over the past 12 months, 6 insiders at Alkermes plc. filed 23 open-market SEC Form 4 transactions on ALKS: 0 purchases worth $0 and 23 sales worth $6.0M. Insiders have been net sellers over this period. The most recent filing was on Jul 6, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 6, 26 | David Joseph GaffinEVP, CLO, Alkermes, Inc. | SELL | 2.0K | $54.03 | $110K |
| Jun 12, 26 | Christopher I Wright | SELL | 2.0K | $45.10 | $90K |
| Jun 4, 26 | David Joseph GaffinEVP, CLO, Alkermes, Inc. | SELL | 2.0K | $43.05 | $88K |
| Jun 1, 26 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 9.0K | $41.67 | $375K |
| May 29, 26 | Samuel Joseph ParisiVP, Finance (Interim PAO) | SELL | 16.2K | $42.36 | $687K |
| May 4, 26 | David Joseph GaffinEVP, CLO, Alkermes, Inc. | SELL | 2.0K | $33.20 | $68K |
| May 1, 26 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 9.0K | $33.40 | $301K |
| Apr 6, 26 | David Joseph GaffinEVP, CLO, Alkermes, Inc. | SELL | 2.0K | $34.57 | $70K |
| Mar 3, 26 | David Joseph GaffinEVP, CLO, Alkermes, Inc. | SELL | 2.0K | $29.76 | $61K |
| Mar 2, 26 | David Joseph GaffinEVP, CLO, Alkermes, Inc. | SELL | 2.0K | $29.29 | $60K |
| Mar 2, 26 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 9.0K | $29.72 | $267K |
| Mar 2, 26 | Christian Todd NicholsSVP, Chief Commercial Officer | SELL | 6.0K | $30.00 | $180K |
| Mar 2, 26 | Samuel Joseph ParisiVP, Finance (Interim PAO) | SELL | 6.9K | $29.29 | $202K |
| Feb 2, 26 | Shane CookeDirector | SELL | 32.1K | $34.78 | $1.1M |
| Feb 2, 26 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 5.0K | $34.24 | $171K |
| Jan 8, 26 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 5.0K | $30.00 | $150K |
| Jan 2, 26 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 4.0K | $28.00 | $112K |
| Dec 3, 25 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 3.7K | $30.00 | $112K |
| Dec 1, 25 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 4.0K | $29.30 | $117K |
| Nov 3, 25 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 9.0K | $30.38 | $273K |
| Oct 15, 25 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 9.0K | $31.53 | $284K |
| Jun 10, 25 | Christian Todd NicholsSVP, Chief Commercial Officer | SELL | 3.3K | $31.09 | $104K |
| Jun 9, 25 | Christian Todd NicholsSVP, Chief Commercial Officer | SELL | 3.3K | $31.95 | $106K |
| Feb 28, 25 | Samuel Joseph ParisiVP, Finance (Interim PAO) | SELL | 1.9K | $34.00 | $66K |
| Feb 25, 25 | Samuel Joseph ParisiVP, Finance (Interim PAO) | SELL | 3.7K | $35.26 | $132K |
| Feb 20, 25 | Samuel Joseph ParisiVP, Finance (Interim PAO) | SELL | 1.3K | $35.69 | $47K |
| Feb 13, 25 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 108.8K | $36.02 | $3.9M |
| Feb 12, 25 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 171.8K | $33.27 | $5.6M |
| Jan 30, 25 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 100.9K | $32.05 | $3.2M |
| Dec 9, 24 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 61.2K | $32.07 | $2.0M |
| Dec 9, 24 | Cato T LaurencinDirector | SELL | 2.7K | $31.85 | $86K |
| Dec 5, 24 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 9.2K | $31.50 | $290K |
| Dec 4, 24 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 14.3K | $30.77 | $442K |
| Nov 27, 24 | Christian Todd NicholsSVP, Chief Commercial Officer | SELL | 5.2K | $29.15 | $152K |
| Nov 11, 24 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 59.0K | $30.08 | $1.8M |
| Nov 6, 24 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | SELL | 10.5K | $29.53 | $309K |
| Mar 18, 24 | Christian Todd NicholsSVP, Chief Commercial Officer | SELL | 10.4K | $28.10 | $293K |
| Feb 27, 24 | Samuel Joseph ParisiVP, Finance (Interim PAO) | SELL | 2.6K | $29.65 | $76K |
| Feb 15, 24 | Cato T LaurencinDirector | SELL | 2.7K | $31.85 | $86K |
| Jun 8, 23 | Cato T LaurencinDirector | SELL | 2.6K | $31.85 | $84K |
| Jun 7, 23 | Cato T LaurencinDirector | SELL | 2.8K | $31.50 | $88K |
| May 30, 23 | Christian Todd NicholsSVP, Chief Commercial Officer | SELL | 27.1K | $28.93 | $785K |
| May 9, 23 | Nancy WysenskiDirector | SELL | 41.3K | $31.24 | $1.3M |
| Nov 14, 22 | David Angelo Daglio Jr.Director | BUY | 35.0K | $23.31 | $816K |
| Jun 21, 22 | Christian Todd NicholsSVP, Chief Commercial Officer | SELL | 7.5K | $28.26 | $211K |
| May 17, 22 | Michael J LandineSVP, Corp Dev., Alkermes, Inc. | SELL | 50.0K | $29.15 | $1.5M |
| May 10, 22 | Michael J LandineSVP, Corp Dev., Alkermes, Inc. | SELL | 25.0K | $27.22 | $681K |
| May 6, 22 | Richard F PopsDirector and CEO, Alkermes plc | SELL | 93.7K | $27.85 | $2.6M |
| May 5, 22 | Richard F PopsDirector and CEO, Alkermes plc | SELL | 221.2K | $28.59 | $6.2M |
| May 3, 22 | Michael J LandineSVP, Corp Dev., Alkermes, Inc. | SELL | 25.0K | $28.62 | $716K |
Over the past 12 months, insiders at Alkermes plc. filed 0 open-market purchases worth $0 and 23 sales worth $6.0M on ALKS, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 6, 26.
The largest recent open-market ALKS insider purchase in our data was $816K by David Angelo Daglio Jr., Director, filed on Nov 14, 22.
6 different insiders at Alkermes plc. filed open-market SEC Form 4 transactions on ALKS over the last 12 months.
InsiderTape plots every ALKS insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Alkermes plc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →